With the rapid development of gene editing technology, especially the extensive application of CRISPR technology in recent years, humans have gained the unprecedented ability to change and modify the genome. CRISPR technology is derived from the bacteria’s own “immune system” against bacteriophage. This technology utilizes single-stranded guide RNA (sgRNA) and the Cas9 protein to enable simple, rapid, and low-cost gene editing in vivo and in vitro. Using CRISPR technology, people can not only effectively edit the coding gene and perform the large-scale genome screening, but also can combine with Next Generation Sequencing (NGS) to study the function of non-coding RNA (ncRNA).
Nowadays, CRISPR technology has been widely used in various laboratories around the world. Researchers are able to achieve the artificial gene modification on almost all cell lines and most commonly used experimental animals. Meanwhile, CRISPR gene editing technology has broad prospects and great potential for development in the study of human genetic diseases, viral infection diseases and cancer research.
Mammalian Cell Gene/Genome Editing Procedure
Mammalian Cell Gene/Genome Editing Research Design
- Mammalian cell gene knock-out/knock-in
- Non-coding RNAfunction of mammalian cells
Mammal Gene Editing Service Advantages
- One-stop service
- Proprietary technology platform
- sgRNA library synthesis
- High-throughput function screening platform
Synbio Technologies provides total solutions from sgRNA design, synthesis and activity detection to the construction and screening of stable cell lines or animal models.
With proprietary sgRNA design software, we can efficiently and accurately provide multi-species sequence design solutions.
Patented Syno® 3.0 chip synthesis platform with 95%+ library build coverage.
Synbio Technologies provides high-throughput screening of whole-genome libraries for parallel analysis of gene function in large numbers of cells and the identification of relevant candidate genes.
Ran, F.A., et al., Genome engineering using the CRISPR-Cas9 system. Nature Protocols, 2013. 8(11): p. 2281-2308